Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL-Reference-Cited by-同舟云学术

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

Published:2016-05-19 Issue:20 Volume:127 Page:2411-2415
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Barr Paul M.¹^ORCID,Saylors Gene B.²,Spurgeon Stephen E.³,Cheson Bruce D.⁴,Greenwald Daniel R.⁵,O’Brien Susan M.⁶,Liem Andre K. D.⁷,Mclntyre Rosemary E.⁸,Joshi Adarsh⁹,Abella-Dominicis Esteban⁹,Hawkins Michael J.⁹,Reddy Anita⁹,Di Paolo Julie⁹,Lee Hank⁹,He Joyce⁹,Hu Jing⁹,Dreiling Lyndah K.⁹,Friedberg Jonathan W.¹

Affiliation:

1. James P. Wilmot Cancer Center Institute, University of Rochester Medical Center, Rochester, NY;

2. Charleston Hematology/Oncology Associates, Charleston, SC;

3. Oregon Health & Science University, Portland, OR;

4. Georgetown University Medical Center, Washington, DC;

5. Cancer Center of Santa Barbara, Santa Barbara, CA;

6. University of California, Irvine, Irvine, CA;

7. Pacific Shores Medical Group, Long Beach, CA;

8. Ventura Oncology, Ventura, CA; and

9. Gilead Sciences Inc., Foster City, CA

Abstract

Key Points Concomitant PI3Kδ and SYK inhibition resulted in treatment-emergent pneumonitis, necessitating early study termination. Initial trials of novel combinations should use conservative designs that are focused on safety.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/20/2411/1393258/2411.pdf

Reference21 articles.

1. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.;Lannutti;Blood,2011

2. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.;Currie;J Med Chem,2014

3. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.;Burke;Oncotarget,2014

4. Revised response criteria for malignant lymphoma.;Cheson;J Clin Oncol,2007

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma;Blood Advances;2024-09-24

2. Spleen tyrosine kinase (SYK): an emerging target for the assemblage of small molecule antitumor agents;Expert Opinion on Investigational Drugs;2024-08-11

3. Holding the therapy in CLLp53: mechanisms to achieve durable responses;Anti-Cancer Drugs;2024-08-09

4. Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review;Targeted Oncology;2024-06-19

5. Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial;Nature Medicine;2024-06-17